Tissue plasminogen activator for acute ischaemic stroke

Stephen M Davis, Peter J Hand and Geoffrey A Donnan
Med J Aust 2008; 188 (8): . || doi: 10.5694/j.1326-5377.2008.tb01733.x
Published online: 21 April 2008

In reply: Stroke experts around the world consider that the evidence for thrombolysis with tissue plasminogen activator (tPA) within 3 hours is overwhelming. Licensing authorities such as the Therapeutic Goods Administration in Australia and the Food and Drug Administration in the United States have approved use of tPA after rigorous, independent analysis of all the available data. However, it seems that a minority of sceptical emergency physicians remains, who will probably never be convinced. Further trials in the sub-3-hour time window are unlikely to receive ethical approval. The focus of stroke research has now moved on. Current targets include expansion of the time window and alternative approaches to recanalisation such as intra-arterial thrombolysis and clot retrieval.

  • Stephen M Davis1
  • Peter J Hand2
  • Geoffrey A Donnan3

  • 1 Department of Neurology, Melbourne Neuroscience Centre, Melbourne, VIC.
  • 2 Department of Neurology, Royal Melbourne Hospital, Melbourne, VIC.
  • 3 National Stroke Research Institute, Melbourne, VIC.



remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.